NCT02785185View on ClinicalTrials.gov

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 2, 2016

Study Completion Date

January 31, 2017

Conditions

Psoriasis

Interventions

DRUG

IDP-122 Vehicle Lotion

Vehicle

DRUG

IDP-122 Vehicle Cream

Vehicle

DRUG

IDP-122 Lotion

Lotion

DRUG

Ultravate Cream

Cream

Trial Locations (13)

27262

Valeant Site 02, High Point

32771

Valeant Site 03, Sanford

33134

Valeant Site 07, Coral Gables

33162

Valeant Site 11, North Miami Beach

40202

Valeant Site 04, Louisville

47150

Valeant Site 08, Albany

55432

Valeant Site 06, Fridley

75758

Valeant Site 05, Rogers

77065

Valeant Site 01, Houston

90045

Valeant Site 13, Los Angeles

90210

Valeant Site 10, Beverly Hills

90404

Valeant Site 12, Santa Monica

92008

Valeant Site 09, Carlsbad

All Listed Sponsors

lead

Bausch Health Americas, Inc.

INDUSTRY

NCT02785185 - Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter